CAPRICOR THERAPEUTICS INC (CAPR) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:CAPR • US14070B3096

24.72 USD
+1.69 (+7.34%)
At close: Feb 6, 2026
25.2 USD
+0.48 (+1.94%)
After Hours: 2/6/2026, 8:21:15 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

4

CAPR gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 523 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for CAPR as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, CAPR is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • CAPR had negative earnings in the past year.
  • CAPR had a negative operating cash flow in the past year.
  • CAPR had negative earnings in each of the past 5 years.
  • In the past 5 years CAPR reported 4 times negative operating cash flow.
CAPR Yearly Net Income VS EBIT VS OCF VS FCFCAPR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -10M -20M -30M -40M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -64.85%, CAPR is in line with its industry, outperforming 40.19% of the companies in the same industry.
  • CAPR has a Return On Equity (-97.76%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -64.85%
ROE -97.76%
ROIC N/A
ROA(3y)-39.87%
ROA(5y)-41.5%
ROE(3y)-124.19%
ROE(5y)-96.97%
ROIC(3y)N/A
ROIC(5y)N/A
CAPR Yearly ROA, ROE, ROICCAPR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400

1.3 Margins

  • CAPR does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CAPR Yearly Profit, Operating, Gross MarginsCAPR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • CAPR does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CAPR has more shares outstanding
  • Compared to 5 years ago, CAPR has more shares outstanding
  • CAPR has a better debt/assets ratio than last year.
CAPR Yearly Shares OutstandingCAPR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
CAPR Yearly Total Debt VS Total AssetsCAPR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

  • CAPR has an Altman-Z score of 11.40. This indicates that CAPR is financially healthy and has little risk of bankruptcy at the moment.
  • CAPR has a better Altman-Z score (11.40) than 83.24% of its industry peers.
  • There is no outstanding debt for CAPR. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 11.4
ROIC/WACCN/A
WACC8.85%
CAPR Yearly LT Debt VS Equity VS FCFCAPR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 3.59 indicates that CAPR has no problem at all paying its short term obligations.
  • The Current ratio of CAPR (3.59) is comparable to the rest of the industry.
  • A Quick Ratio of 3.59 indicates that CAPR has no problem at all paying its short term obligations.
  • CAPR's Quick ratio of 3.59 is in line compared to the rest of the industry. CAPR outperforms 45.14% of its industry peers.
Industry RankSector Rank
Current Ratio 3.59
Quick Ratio 3.59
CAPR Yearly Current Assets VS Current LiabilitesCAPR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. Growth

3.1 Past

  • CAPR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -69.81%.
  • The Revenue for CAPR has decreased by -52.08% in the past year. This is quite bad
  • The Revenue has been growing by 85.64% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-69.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.11%
Revenue 1Y (TTM)-52.08%
Revenue growth 3Y352.73%
Revenue growth 5Y85.64%
Sales Q2Q%-100%

3.2 Future

  • CAPR is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.19% yearly.
  • CAPR is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 90.58% yearly.
EPS Next Y-83.41%
EPS Next 2Y-14.49%
EPS Next 3Y27.38%
EPS Next 5Y35.19%
Revenue Next Year-96.42%
Revenue Next 2Y149.49%
Revenue Next 3Y101.72%
Revenue Next 5Y90.58%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
CAPR Yearly Revenue VS EstimatesCAPR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
CAPR Yearly EPS VS EstimatesCAPR Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5 10 -10 15

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CAPR. In the last year negative earnings were reported.
  • Also next year CAPR is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CAPR Price Earnings VS Forward Price EarningsCAPR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CAPR Per share dataCAPR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CAPR's earnings are expected to grow with 27.38% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.49%
EPS Next 3Y27.38%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • CAPR does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CAPRICOR THERAPEUTICS INC

NASDAQ:CAPR (2/6/2026, 8:21:15 PM)

After market: 25.2 +0.48 (+1.94%)

24.72

+1.69 (+7.34%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-10
Earnings (Next)03-17
Inst Owners32.19%
Inst Owner Change-3.62%
Ins Owners1.16%
Ins Owner Change0.02%
Market Cap1.13B
Revenue(TTM)11.13M
Net Income(TTM)-81.99M
Analysts83.75
Price Target51.82 (109.63%)
Short Float %13.42%
Short Ratio1.65
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-7.94%
Min EPS beat(2)-19.18%
Max EPS beat(2)3.3%
EPS beat(4)2
Avg EPS beat(4)-9.88%
Min EPS beat(4)-64.08%
Max EPS beat(4)40.43%
EPS beat(8)4
Avg EPS beat(8)-16.23%
EPS beat(12)8
Avg EPS beat(12)-6.77%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)-51.98%
Min Revenue beat(4)-100%
Max Revenue beat(4)92.08%
Revenue beat(8)3
Avg Revenue beat(8)-34.76%
Revenue beat(12)7
Avg Revenue beat(12)1598.21%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)146.6%
EPS NQ rev (1m)-5.65%
EPS NQ rev (3m)-1.41%
EPS NY rev (1m)0%
EPS NY rev (3m)1.08%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-54.63%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 101.54
P/FCF N/A
P/OCF N/A
P/B 13.48
P/tB 13.48
EV/EBITDA N/A
EPS(TTM)-1.8
EYN/A
EPS(NY)-1.57
Fwd EYN/A
FCF(TTM)-1.5
FCFYN/A
OCF(TTM)-1.34
OCFYN/A
SpS0.24
BVpS1.83
TBVpS1.83
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -64.85%
ROE -97.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-39.87%
ROA(5y)-41.5%
ROE(3y)-124.19%
ROE(5y)-96.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.09
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 416.19%
Cap/Sales 65.89%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.59
Quick Ratio 3.59
Altman-Z 11.4
F-Score2
WACC8.85%
ROIC/WACCN/A
Cap/Depr(3y)311.17%
Cap/Depr(5y)361.27%
Cap/Sales(3y)48.94%
Cap/Sales(5y)164.85%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-69.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-42.11%
EPS Next Y-83.41%
EPS Next 2Y-14.49%
EPS Next 3Y27.38%
EPS Next 5Y35.19%
Revenue 1Y (TTM)-52.08%
Revenue growth 3Y352.73%
Revenue growth 5Y85.64%
Sales Q2Q%-100%
Revenue Next Year-96.42%
Revenue Next 2Y149.49%
Revenue Next 3Y101.72%
Revenue Next 5Y90.58%
EBIT growth 1Y-139.8%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-127.06%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-191.7%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-192.06%
OCF growth 3YN/A
OCF growth 5YN/A

CAPRICOR THERAPEUTICS INC / CAPR FAQ

What is the fundamental rating for CAPR stock?

ChartMill assigns a fundamental rating of 4 / 10 to CAPR.


What is the valuation status of CAPRICOR THERAPEUTICS INC (CAPR) stock?

ChartMill assigns a valuation rating of 1 / 10 to CAPRICOR THERAPEUTICS INC (CAPR). This can be considered as Overvalued.


What is the profitability of CAPR stock?

CAPRICOR THERAPEUTICS INC (CAPR) has a profitability rating of 1 / 10.